Better Times Ahead For Regenxbio Inc (NASDAQ: RGNX)?

Regenxbio Inc (RGNX) concluded trading on Thursday at a closing price of $21.07, with 0.49 million shares of worth about $10.26 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.72% during that period and on March 28, 2024 the price saw a loss of about -5.00%. Currently the company’s common shares owned by public are about 44.05M shares, out of which, 43.91M shares are available for trading.

Stock saw a price change of -6.36% in past 5 days and over the past one month there was a price change of 5.88%. Year-to-date (YTD), RGNX shares are showing a performance of 17.38% which increased to 11.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $11.83 but also hit the highest price of $28.80 during that period. The average intraday trading volume for Regenxbio Inc shares is 796.06K. The stock is currently trading -4.85% below its 20-day simple moving average (SMA20), while that difference is up 16.29% for SMA50 and it goes to 17.34% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Regenxbio Inc (NASDAQ: RGNX) currently have 44.05M outstanding shares and institutions hold larger chunk of about 79.14% of that.

The stock has a current market capitalization of $1.03B and its 3Y-monthly beta is at 1.30. It has posted earnings per share of -$6.03 in the same period. It has Quick Ratio of 2.57 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RGNX, volatility over the week remained 5.15% while standing at 8.72% over the month.

Analysts are in expectations that Regenxbio Inc (RGNX) stock would likely to be making an EPS of -$1.26 in the current quarter, while forecast for next quarter EPS is -$1.22 and it is -$2.19 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.5 which is -$1.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.53 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 31.73% while it is estimated to increase by 49.94% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on March 11, 2024 offering a Buy rating for the stock and assigned a target price of $36 to it. Coverage by RBC Capital Mkts stated Regenxbio Inc (RGNX) stock as an Outperform in their note to investors on March 08, 2024, suggesting a price target of $35 for the stock. On March 06, 2024, Leerink Partners Upgrade their recommendations, while on February 21, 2024, Raymond James Resumed their ratings for the stock with a price target of $45. Stock get a Buy rating from Stifel on November 01, 2023.

Most Popular

Related Posts